迄今为止的证据：雷珠单抗及其在治疗早产儿视网膜病变中的潜力

IF 3.1 Q1 OPHTHALMOLOGY Eye and Brain Pub Date : 2019-08-23 DOI:10.2147/EB.S189684

Samir N. Patel, M. Klufas

{"title":"迄今为止的证据：雷珠单抗及其在治疗早产儿视网膜病变中的潜力","authors":"Samir N. Patel, M. Klufas","doi":"10.2147/EB.S189684","DOIUrl":null,"url":null,"abstract":"Abstract Retinopathy of prematurity (ROP) is a leading and preventable cause of childhood blindness worldwide. Although laser photocoagulation remains the gold standard for treatment, the off-label use of anti-vascular endothelial growth factor (anti-VEGF) therapy to treat ROP, particularly posterior zone I disease, is increasing. Although initial studies on anti-VEGF therapy for ROP have focused on bevacizumab, recent studies have proposed that ranibizumab may be a safer and more effective alternative for use in this population. This review updates recent evidence regarding the use of ranibizumab in the management of ROP.","PeriodicalId":51844,"journal":{"name":"Eye and Brain","volume":"11 1","pages":"25 - 35"},"PeriodicalIF":3.1000,"publicationDate":"2019-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/EB.S189684","citationCount":"12","resultStr":"{\"title\":\"Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity\",\"authors\":\"Samir N. Patel, M. Klufas\",\"doi\":\"10.2147/EB.S189684\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Retinopathy of prematurity (ROP) is a leading and preventable cause of childhood blindness worldwide. Although laser photocoagulation remains the gold standard for treatment, the off-label use of anti-vascular endothelial growth factor (anti-VEGF) therapy to treat ROP, particularly posterior zone I disease, is increasing. Although initial studies on anti-VEGF therapy for ROP have focused on bevacizumab, recent studies have proposed that ranibizumab may be a safer and more effective alternative for use in this population. This review updates recent evidence regarding the use of ranibizumab in the management of ROP.\",\"PeriodicalId\":51844,\"journal\":{\"name\":\"Eye and Brain\",\"volume\":\"11 1\",\"pages\":\"25 - 35\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2019-08-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2147/EB.S189684\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eye and Brain\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/EB.S189684\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eye and Brain","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/EB.S189684","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 12

摘要

摘要早产儿视网膜病变（ROP）是世界范围内儿童失明的主要且可预防的原因。尽管激光光凝仍然是治疗的金标准，但抗血管内皮生长因子（anti-VEGF）治疗ROP，特别是后I区疾病的标签外使用正在增加。尽管最初对ROP抗VEGF治疗的研究集中在贝伐单抗上，但最近的研究表明，在这一人群中使用雷珠单抗可能是一种更安全、更有效的替代方案。这篇综述更新了关于使用雷尼珠单抗治疗ROP的最新证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity

Abstract Retinopathy of prematurity (ROP) is a leading and preventable cause of childhood blindness worldwide. Although laser photocoagulation remains the gold standard for treatment, the off-label use of anti-vascular endothelial growth factor (anti-VEGF) therapy to treat ROP, particularly posterior zone I disease, is increasing. Although initial studies on anti-VEGF therapy for ROP have focused on bevacizumab, recent studies have proposed that ranibizumab may be a safer and more effective alternative for use in this population. This review updates recent evidence regarding the use of ranibizumab in the management of ROP.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Eye and Brain OPHTHALMOLOGY-

CiteScore

7.90

自引率

2.30%

发文量

审稿时长

16 weeks

期刊介绍： Eye and Brain is an international, peer-reviewed, open access journal focusing on basic research, clinical findings, and expert reviews in the field of visual science and neuro-ophthalmology. The journal’s unique focus is the link between two well-known visual centres, the eye and the brain, with an emphasis on the importance of such connections. All aspects of clinical and especially basic research on the visual system are addressed within the journal as well as significant future directions in vision research and therapeutic measures. This unique journal focuses on neurological aspects of vision – both physiological and pathological. The scope of the journal spans from the cornea to the associational visual cortex and all the visual centers in between. Topics range from basic biological mechanisms to therapeutic treatment, from simple organisms to humans, and utilizing techniques from molecular biology to behavior. The journal especially welcomes primary research articles or review papers that make the connection between the eye and the brain. Specific areas covered in the journal include: Physiology and pathophysiology of visual centers, Eye movement disorders and strabismus, Cellular, biochemical, and molecular features of the visual system, Structural and functional organization of the eye and of the visual cortex, Metabolic demands of the visual system, Diseases and disorders with neuro-ophthalmic manifestations, Clinical and experimental neuro-ophthalmology and visual system pathologies, Epidemiological studies.